| Similar Articles |
|---|
 |
Chemistry World
January 23, 2015
Rebecca Trager |
Obama talks up research, announces personalized medicine initiative President Obama has highlighted the importance of research and innovation to the health of the US economy and its citizens.   |
Chemistry World
January 27, 2012
Sarah Houlton |
Illumina fends off Roche hostile bid Roche has made a $5.7 billion hostile bid for the genome sequencing company Illumina, after the San Diego, US-based company rejected its initial approach. |
Bio-IT World
April 2007 |
News Briefs Molecular Medicine's "Best of Show"... Dissolving Assets... Combined Forces... |
Bio-IT World
November 14, 2003
Kathy Ordonez |
Targeted Medicine via Molecular Diagnostics Using diagnostics to select and deselect target populations for drug therapy will enable life scientists to make more effective medicines. |
Chemistry World
July 2010
Anna Lewcock |
Medicine made to measure Healthcare tailored to suit the genetic makeup of the patient is finally coming to fruition. |
Fast Company
January 2002
George Anders |
Roche's New Scientific Method How does a giant pharmaceutical company reckon with genomics technology? By making a fresh start in how it recruits its scientists, manages projects, and uses computers. Here's how the Roche Group is reinventing how it invents... |
Chemistry World
August 29, 2014
Sarah Houlton |
Roche to buy InterMune for respiratory boost Roche is to acquire InterMune in a deal worth $8.3 billion. |
BusinessWeek
October 1, 2007
Conrad Wilson |
A Dream Team Of Drugs And Diagnosis? If a deal is struck, a Roche-Ventana team could help launch a medical revolution. |
BusinessWeek
September 5, 2005
Capell & Arndt |
Drugs Get Smart Future medicines will more effectively target what ails you by tailoring treatment to your specific genetic profile. Personalized medicine will also help prevent another Vioxx. |
BusinessWeek
August 26, 2010
Tom Randall |
Cocktails Are Next For Cancer-Drug Makers Taking a cue from the cocktails of drugs that have made AIDS survivable, drugmakers are pursuing combination therapies against cancer. |
BusinessWeek
September 5, 2005
Kerry Capell |
Meeting Leukemia's Diagnostic Challenge Tests that distinguish among the disease's many forms either cost too much or don't exist. Dr. Torsten Haferlach And Switzerland's Roche Diagnostics may have a solution. |
The Motley Fool
October 27, 2010
Ralph Casale |
Companion Diagnostics in Cancer Drug Development Diagnostic companies partnering with drug developers can make for an attractive investment segment. |
Pharmaceutical Executive
March 1, 2011
Jerry Coamey |
Engage the Physician! New research shows that gauging the mind of the clinician is crucial to timely uptake of the new diagnostic tools offered by the genomic revolution |
Bio-IT World
February 11, 2005
Robert M. Frederickson |
Genomics Drives New Crop of IVDs In vitro diagnostic microarrays are an important tool in oncology. The Affymetrix GeneChip System 3000Dx (GCS 3000Dx) was the first microarray instrument to be cleared by the FDA for IVD use. |
Pharmaceutical Executive
February 1, 2013
William Looney |
Pathways to Progress Cancer is increasingly understood as a collection of rare and mostly treatable conditions rather than the impregnable, monolith portrayed in popular culture. Industry experts review current and pending efforts to turn great science into good practice. |
The Motley Fool
October 25, 2005
Brian Gorman |
Albany Molecular's Mixed Bag The pharma's contract services side is improving, and Allegra royalties won't disappear. Even so, the company seems to be facing some tough times ahead. Investors, take note. |
The Motley Fool
August 29, 2011
Brian Orelli |
Drug Approved for Few Patients -- but That's OK The age of personalized medicine is upon us. Earlier this month, the FDA approved Roche's melanoma drug Zelboraf for patients with a specific mutation in BRAF. And on Friday, the agency approved Pfizer's Xalkori for lung cancer patients that are ALK-positive. |
Pharmaceutical Executive
May 1, 2007 |
Deals: Roche Goes Shopping BioVeris purchase locks in a key diagnostic technology... Eisai buys Morphotek... IMS gets more outcomes-research muscle... etc. |
Bio-IT World
December 15, 2003
Kevin Davies |
The Road to Personalized Medicine FDA guidance on the road to genomic medicine is a welcome first step in what promises to be a contentious debate on how to integrate pharmacogenomics into routine medical practice. |
Pharmaceutical Executive
September 1, 2011
Don Creighton |
Bridging the Hidden Hurdle in Cancer Cures Diagnostics can boast the efficacy of drug treatments, but delivering the promise depends on a predictable pathway to reimbursement. |
BusinessWeek
November 25, 2009
Arlene Weintraub |
Can Roche Leave Genentech Alone? Now that Roche has acquired the biotech superstar, success will depend on keeping some distance. |
Bio-IT World
October 9, 2002
Malorye Branca |
The Path to Personalized Medicine The tactics have changed, sometimes dramatically, but hints of the promise of pharmacogenomics are finally starting to trickle in from studies of asthma, cancer, and drug response. |
Chemistry World
August 6, 2013
Phillip Broadwith |
Antiviral patents released by Roche A five-year agreement between Roche and Unitaid's Medicines Patent Pool will make more antiviral drugs available at knock-down prices in developing countries. |
The Motley Fool
September 14, 2011
Frank Vinluan |
Here's How New Roche Cancer Drug Zelboraf Benefits LabCorp A new Roche cancer drug expected to become a blockbuster could also end up being a boon for laboratory and diagnostics firm LabCorp. |
BusinessWeek
June 13, 2005
Catherine Arnst |
Biotech, Finally The past 30 years of biological discoveries, insights into the human genome, and exotic chemical manipulation have unleashed a wave of biological drugs, many of them reengineered human proteins. |
The Motley Fool
June 7, 2011
Brian Orelli |
Sometimes a Partnership Feels Personal Merck and Roche hook up for a diagnostic drug deal. |
Chemistry World
June 26, 2012
Sarah Houlton |
Roche rapped for side-effect reporting failure Roche has been rapped by the European Medicines Agency for failing to report a large number of potential drug side-effects. The UK's Medicines and Healthcare products Regulatory Agency identified deficiencies in the company's medicine safety reporting system. |
Chemistry World
September 7, 2015 |
Cancer Drugs Fund axes 23 treatments The Cancer Drugs Fund, which covers the cost of some cancer treatments that are not currently available on the National Health Service, has cut 23 treatments -- involving 16 drugs. |
Chemistry World
April 5, 2013
Phillip Broadwith |
Roche to release Tamiflu trial data Swiss pharma company Roche has finally agreed to give independent researchers access to data on all 74 clinical trials it ran on the antiviral influenza drug Tamiflu (oseltamivir). |
The Motley Fool
July 11, 2007
Brian Orelli |
Everybody Loves RNAi Roche is the latest firm to (over)pay for the hottest new drug technology. Alnylam announced that it licensed some of its intellectual property to Roche for $331 million. Investors, take note. |
The Motley Fool
February 29, 2008
Brian Lawler |
Amgen Playing Hardball There are new developments in the Amgen and Roche patent fight over their anemia drugs. |
BusinessWeek
June 16, 2011
Langreth & Cortez |
When Two Cancer Drugs Are Better Than One Drugmakers are collaborating to test combinations of genetically targeted cancer drugs in hopes of boosting survival rates. |
Pharmaceutical Executive
November 1, 2005
Sarah Houlton |
Global Report: Drug Evaluation in the UK The availability of new medicines has been thrown into the limelight once more, with UK's National Institute for Health and Clinical Excellence being called upon to make dramatic improvements to the speed at which it carries out evaluations. |
BusinessWeek
June 13, 2005
John Carey |
The NIH's Roadmap for Research Charting the human genome was just the beginning. Now the focus is creating pathways that will lead to practical applications. |
BusinessWeek
July 1, 2010
Doherty & Waters |
Post-Buyout, Genentech's DNA Is Dominant Bought out for $47 billion, the biotech pioneer has gained the upper hand |
The Motley Fool
August 27, 2010
Brian Orelli |
Down 35%! This Just Shouldn't Happen Someone's to blame and it isn't ImmunoGen. |
The Motley Fool
July 20, 2005
Stephen D. Simpson |
Two Ways to Play Roche Trying to track Roche is a pain, so investors might want to think about Genentech instead. |
Chemistry World
October 15, 2013
Emily James |
Roche backs biologic boom The world's largest biotech company, Roche, has announced it will invest 800 million Swiss francs into manufacturing biological medicines over the next five years. |
The Motley Fool
August 14, 2008
Brian Lawler |
Genentech Asks Roche to Pay Up In one of the more friendly spurnings of a buyout offer in recent months, Genentech calls Roche's $89-per-share buyout offer too low, and very nicely implies that Roche should up its bid. |
Bio-IT World
August 18, 2004
Mark D. Uehling |
I, Virtual Patient Along with a software company specializing in modeling diseases on the computer, Roche Diagnostics is working on creating a new biomarker for diabetes that could be reduced to a simple blood test. |
The Motley Fool
October 17, 2006
Brian Lawler |
Roche Rocks The Swiss pharma has a stable of hot brands and lots of promise in the pipeline. Investors, this may be a pharmaceutical worth looking at. |
The Motley Fool
August 22, 2007
Brian Orelli |
Yes? No? Maybe So? Roche is still after Ventana. While longtime investors are happy that Roche pointed out Ventana's undervaluation to the rest of the world, current investors think Roche's offer is still too low. |
Chemistry World
June 9, 2015
Phillip Broadwith |
Opko deepens diagnostics with $1.5bn lab buyout Healthcare firm Opko is aiming to enhance its position in diagnostic technology by agreeing to buy clinical diagnostics service BioReference Laboratories. |
Chemistry World
June 16, 2014
Jennifer Newton |
Ahmed Elmouna: Oligos in the desert Ahmed Elmouna is head of analytical chemistry in the molecular diagnostics and personalized therapeutics unit at the University of Ha'il in Saudi Arabia. |
The Motley Fool
July 21, 2008
Brian Lawler |
Roche Wants to Buy Genentech -- Again In what could become one of the biggest biotech deals ever, Roche announces that it is offering to pay $43.7 billion for the remaining Genentech shares it doesn't already own. |
The Motley Fool
December 11, 2006
Brian Lawler |
Roche's Early Present to Halozyme Assuming it works, Enhanze may be a platform technology that could be applied across a wide range of injected products. Roche isn't exactly betting the farm on its success, though, with only $20 million of guaranteed up-front money. Investors, take note. |
Pharmaceutical Executive
September 1, 2013
William Looney |
High Noon For Hot Markets Fading growth, overstretched governments, and a global governance backlash against pharma business are turning up the heat on the performance of emerging country markets. |
The Motley Fool
November 10, 2006
Brian Gorman |
Albany Molecular Plays the Odds Third-quarter results show that the chemistry services outfit continued to slog through some tough times. Heightened activity in its riskier side business suggests that 2007 might not bring a fatter bottom line. |
The Motley Fool
June 3, 2011
Brian Orelli |
Tag-Teaming Melanoma for Fun and Profit Bristol-Myers Squibb and Roche hook up. |
The Motley Fool
March 19, 2008
Brian Lawler |
Roche to Amgen: We Surrender Roche gives in to a judge's recommendation that it pay a higher royalty to Amgen on sales of its anemia drug Mircera. |
